Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Products under Development by Stage of Development | 9 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Products under Development by Therapy Area | 10 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Products under Development by Indication | 11 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Products under Development by Companies | 14 | 2 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Products under Development by Universities/Institutes | 16 | 2 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 24 | 8 |
| AMO Pharma Limited | 24 | 1 |
| Angelini Group | 25 | 1 |
| Celon Pharma Sp. z o.o. | 26 | 1 |
| DiaMedica Inc. | 27 | 1 |
| HitGen LTD | 28 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 29 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 30 | 1 |
| Neurim Pharmaceuticals Ltd | 31 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drug Profiles | 32 | 20 |
| AP-001 Drug Profile | 32 | 1 |
| CPL-202100 Drug Profile | 33 | 1 |
| DM-199 Drug Profile | 34 | 4 |
| DM-204 Drug Profile | 38 | 2 |
| Drug to Inhibit GSK3-Beta for Alzheimer's Disease Drug Profile | 40 | 1 |
| IB-AD Drug Profile | 41 | 1 |
| JGK-263 Drug Profile | 42 | 1 |
| manzamine A Drug Profile | 43 | 1 |
| Neu-120 Drug Profile | 44 | 1 |
| Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies Drug Profile | 45 | 1 |
| Small Molecule to Inhibit GSK3b for Type 2 Diabetes Drug Profile | 46 | 1 |
| Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease Drug Profile | 47 | 1 |
| Small Molecules to Inhibit GSK-3 Beta for CNS Disorders Drug Profile | 48 | 1 |
| Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases Drug Profile | 49 | 1 |
| Small Molecules to Inhibit GSK3 Beta for Type 2 Diabetes, Oncology and Alzheimer s Disease Drug Profile | 50 | 1 |
| tideglusib Drug Profile | 51 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Dormant Projects | 52 | 2 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Discontinued Products | 54 | 1 |
| Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Featured News &Press Releases | 55 | 7 |
| Oct 05, 2016: DiaMedica Announces First Patient Enrolled in Bridging Clinical Trial for DM199 | 55 | 1 |
| Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199 | 55 | 1 |
| Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy | 55 | 1 |
| Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199 | 56 | 1 |
| Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia | 56 | 1 |
| Nov 04, 2015: DiaMedica Provides Corporate Update | 57 | 1 |
| Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference | 58 | 1 |
| Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases | 58 | 1 |
| Nov 17, 2014: DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes | 59 | 1 |
| Aug 07, 2014: DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes | 59 | 1 |
| Jun 10, 2014: DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference | 59 | 1 |
| Feb 19, 2014: DiaMedica announces successful completion of Phase 1 program for DM199 | 60 | 1 |
| Jan 09, 2014: DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients | 60 | 1 |
| Sep 30, 2013: DiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic Patients | 60 | 1 |
| Aug 20, 2013: DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study | 61 | 1 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |
